An increasing body of subsequent research has challenged the usefulness of the healthcare-associated pneumonia label, including studies that have cast doubt on links between multidrug-resistant pathogens and increased mortality.
A multidisciplinary panel of experts put together by the American Thoracic Society and Infectious Diseases Society of America released updated recommendations for the management of adults with community-acquired pneumonia.
A shift toward personalized medicine in pneumonia management would involve refining the diagnostic categories to include viral pneumonia, bacterial pneumonia, and noninfectious respiratory disease.
Inappropriate antibiotic treatment selection or duration as well as lack of microbial evidence of infection were commonly found in patients hospitalized for select event.
Continuous regulation of cuff pressure of the tracheal tube using a pneumatic device was not superior to routine care in preventing ventilator-associated pneumonia in patients experiencing severe trauma.
In many patients with exogenous lipoid pneumonia, respiratory symptoms and radiologic abnormalities continue to worsen even if the culprit exposure is identified and discontinued.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.